Strategies to manage antifungal drug resistance

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 2, 2011, Pages 241-256

  Tseng, Hsiang Kuang ^a,b   Perfect, John R ^c  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical resistance; Combination therapy; Immune reconstitution inflammatory syndrome; Immunotherapy; Microbiological resistance; Pre emptive therapy; Prophylaxis therapy

Indexed keywords

AMPHOTERICIN B; CHEMOKINE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; GALACTOMANNAN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; PENTRAXIN 3; PIPERACILLIN PLUS TAZOBACTAM; POLYENE; PYRROLE; RECOMBINANT GAMMA INTERFERON; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR; VACCINE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS USTUS; CAENORHABDITIS ELEGANS; CANDIDA; CANDIDA ALBICANS; CANDIDA ENDOCARDITIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CELLULAR IMMUNITY; CLAVISPORA LUSITANIAE; CRITICAL ILLNESS; CROSS REACTION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; DENDRITIC CELL; DIAGNOSTIC ERROR; DISEASE SURVEILLANCE; DRUG DELIVERY SYSTEM; DRUG MONITORING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME IMMUNOASSAY; FALSE POSITIVE RESULT; FUNGAL DETECTION; FUNGAL GENE; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; FUNGUS TRANSMISSION; FUSARIUM; GRANULOCYTE; HIGH RISK POPULATION; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INVASIVE CANDIDIASIS; LEUKOCYTE ACTIVATION; MACROPHAGE; MYELOID PROGENITOR CELL; NEOPLASM; NEUTROPHIL COUNT; NONHUMAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; REVIEW; SCEDOSPORIUM APIOSPERMUM; SUPERINFECTION; SYSTEMIC MYCOSIS; TRANSPLANTATION; TRICHOSPORON; TRICHOSPORON BEIGELII; ZYGOMYCETES;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; MYCOSES;

EID: 78651457772     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.517195     Document Type: Review

References (115)

1. Dupont B, Crewe Brown HH, Westermann K, et al. Mycoses in AIDS. Med Mycol 2000;38(Suppl 1):259-67 (Pubitemid 32094074)
2. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007;45:305-20 (Pubitemid 46839801)
3. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010;50:1091-100
4. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003;3:772-85 (Pubitemid 37489961)
5. Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995 - 2004. Pediatrics 2006;117:1680-7 (Pubitemid 46071397)
6. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7 (Pubitemid 36259570)
7. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-17
8. Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 2003;6:197-218 (Pubitemid 37129919)
9. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006;42:1171-8
10. Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther 2005;27:657-73
11. Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis 2008;46:1426-33 (Pubitemid 351589944)
12. Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol 2007;10:436-40 (Pubitemid 350064580)
13. Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis 2005;37:195-9 (Pubitemid 40372843)
14. Brazier JS. Clostridium difficile: from obscurity to superbug. Br J Biomed Sci 2008;65:39-44
15. Verweij PE, Snelders E, Kema GH, et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009;9:789-95
16. Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008;46:120-8
17. McClenny NB, Fei H, Baron EJ, et al. Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob Agents Chemother 2002;46:1325-8 (Pubitemid 34415309)
18. White TC, Holleman S, Dy F, et al. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002;46:1704-13 (Pubitemid 34535186)
19. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Anifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009;47:117-23
20. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006;42:938-44
21. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007;10:121-30
22. Garcia-Effron G, Chua DJ, Tomada JR, et al. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother 2010;54:2225-7
23. Pfeiffer CD, Garcia-Effron G, Zaas AK, et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010;48:2373-80
24. Sun HY, Singh N. Characterization of breakthrough invasive mycoses in echinocandin recipients: an evidence-based reviews. Int J Antimicrob Agents 2010;35:211-18
25. Kabbara N, Lacroix C, Peffault de Latour R, et al. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008;93:639-40 (Pubitemid 351536400)
26. Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001 - 2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009;115:4745-52
27. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008;56:126-9
28. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15 (Pubitemid 34851833)
29. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006;107:2888-97 (Pubitemid 44937044)
30. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008;112:2309-12 (Pubitemid 351628643)
31. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008;14:398-405
32. ESCMID SoASTAot, (EUCAST) ECfAST. EUCAST Definitive Document E.DEF 9.1: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. 2008
33. Lass-Florl C, Mayr A, Perkhofer S, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2008;52:3637-41
34. Canton E, Espinel-Ingroff A, Peman J. Trends in antifungal susceptibility testing using CLSI reference and commercial methods. Expert Rev Anti Infect Ther 2009;7:107-19
35. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35:982-9 (Pubitemid 35178316)
36. Baddley JW, Marr KA, Andes DR, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009;47:3271-5
37. Vos MC, Endtz HP, Horst-Kreft D, et al. Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures. J Clin Microbiol 2006;44:1111-14
38. Benet T, Nicolle MC, Thiebaut A, et al. Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. Clin Infect Dis 2007;45:682-6 (Pubitemid 47378880)
39. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 2009;47:1942-6
40. Breger J, Fuchs BB, Aperis G, et al. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog 2007;3:e18 (Pubitemid 46318416)
41. Meyer V. A small protein that fights fungi: AFP as a new promising antifungal agent of biotechnological value. Appl Microbiol Biotechnol 2008;78:17-28
42. Martinez LR, Mihu MR, Han G, et al. The use of chitosan to damage Cryptococcus neoformans biofilms. Biomaterials 2010;31:669-79
43. Wang J, Wu J. Antifungal activity of 25-azalanosterol against Candida species. Eur J Clin Microbiol Infect Dis 2008;27:1131-6
44. Vale-Silva LA, Goncalves MJ, Cavaleiro C, et al. Antifungal activity of the essential oil of thymus x viciosoi against Candida, Cryptococcus, Aspergillus and Dermatophyte species. Planta Med 2010;76(9):882-8
45. Liu L, Xu K, Wang H, et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol 2009;4:457-63
46. Wang H, Xu K, Liu L, et al. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. Biomaterials 2010;31:2874-81
47. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010;50:291-322
48. Bicanic T, Wood R, Bekker LG, et al. Antiretroviral roll-out, antifungal rollback: access to treatment for cryptococcal meningitis. Lancet Infect Dis 2005;5:530-1 (Pubitemid 41196749)
49. Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009;48:1775-83
50. Harrison TS. Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis. Clin Infect Dis 2009;48:1784-6
51. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
52. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003;37(Suppl 3):S188-224
53. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60 (Pubitemid 351265310)
54. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14 (Pubitemid 33152659)
55. Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006;20:711-27,viii
56. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21
57. Schabereiter-Gurtner C, Selitsch B, Rotter ML, et al. Development of novel real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens. J Clin Microbiol 2007;45:906-14 (Pubitemid 46427710)
58. de Pauw BE, Patterson TF. Should the consensus guidelines specific criteria for the diagnosis of invasive fungal infection be changed? Clin Infect Dis 2005;41(Suppl 6):S377-80
59. Matsue K, Uryu H, Koseki M, et al. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006;42:753-7 (Pubitemid 43363927)
60. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007;39:425-9
61. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5 (Pubitemid 41233011)
62. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31 (Pubitemid 43939072)
63. Dignan FL, Evans SO, Ethell ME, et al. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant 2009;44:51-6
64. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-50 (Pubitemid 41534660)
65. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9
66. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51
67. de Pauw BE, Donnelly JP. Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy? Clin Infect Dis 2009;48:1052-4
68. Perfect JR. Antifungal prophylaxis: to be or not to be, that is still the question. J Invasive Fungal Infect 2007;1:2-3
69. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-8 (Pubitemid 351589940)
70. Perfect JR, Dodds Ashley E, Drew R. Design of aerosolized amphotericin B formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis 2004;39(Suppl 4):S207-10 (Pubitemid 40169348)
71. Perfect JR. Aerosolized antifungal prophylaxis: the winds of change? Clin Infect Dis 2008;46:1409-11
72. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety prophylaxis for fungal infections after marrow transplantation - a prospective, randomized double-blind study. J Infect Dis 1995;171:1545-52
73. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2005-61
74. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59 (Pubitemid 46148777)
75. Mattiuzzi GN, Kantarjian H. Antifungal prophylaxis in patients with hematological cancers. J Invasive Fungal Infect 2007;1:10-6
76. Segal BH, Kwon-Chung J, Walsh TJ, et al. Immunotherapy for fungal infections. Clin Infect Dis 2006;42:507-15
77. Roilides E, Farmaki E. Granulocyte colony-stimulating factor and other cytokines in antifungal therapy. Clin Microbiol Infect 2001;7(Suppl 2):62-7 (Pubitemid 34960254)
78. Neumunaitis J, Shannon-Dorcy K, Appelbaum FR, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993;82:1422-7 (Pubitemid 23263957)
79. BitMansour A, Cao TM, Chao S, et al. Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia. Blood 2005;105:3535-7 (Pubitemid 40628196)
80. Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2009;1:CD005341
81. Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant 2008;42:679-84
82. Stevens DA, Brummer E, Clemons KV. Interferon-gamma as an antifungal. J Infect Dis 2006;194(Suppl 1):S33-7
83. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon - gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004;189:2185-91 (Pubitemid 38757190)
84. Netea MG, Ferwerda G, van der Graaf CA, et al. Recognition of fungal pathogens by toll-like receptors. Curr Pharm Des 2006;12:4195-201 (Pubitemid 44669748)
85. Netea MG, Van Der Graaf CA, Vonk AG, et al. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002;185:1483-9
86. Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009;361:1760-7
87. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359:1766-77
88. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103:4232-9 (Pubitemid 38685368)
89. Gaziano R, Bozza S, Bellocchio S, et al. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother 2004;48:4414-21 (Pubitemid 39434905)
90. Larsen RA, Pappas PG, Perfect J, et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 2005;49:952-8 (Pubitemid 40327709)
91. Martinez LR, Christaki E, Casadevall A. Specific antibody to Cryptococcus neoformans glucurunoxylomannan antagonizes antifungal drug action against cryptococcal biofilms in vitro. J Infect Dis 2006;194:261-6 (Pubitemid 44087199)
92. Rachini A, Pietrella D, Lupo P, et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 2007;75:5085-94 (Pubitemid 350033595)
93. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006;42:1404-13
94. Nooney L, Matthews RC, Burnie JP. Evaluation of mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis 2005;51:19-29 (Pubitemid 40040564)
95. Cowen LE, Singh SD, Kohler JR, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 2009;106:2818-23
96. Singh SD, Robbins N, Zaas AK, et al. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 2009;5:e1000532
97. Torosantucci A, Bromuro C, Chiani P, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005;202:597-606 (Pubitemid 41258184)
98. Pirofski LA, Casadevall A. Immunomodulators as an antimicrobial tool. Curr Opin Microbiol 2006;9:489-95 (Pubitemid 44404173)
99. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004;18:1615-27 (Pubitemid 39095778)
100. Robertson J, Meier M, Wall J, et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006;42:1639-46 (Pubitemid 43752655)
101. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007;110:112-20 (Pubitemid 46986424)
102. Woodworth GF, McGirt MJ, Williams MA, Rigamonti D. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis (discussion 31-2). Surg Neurol 2005;63:529-31 (Pubitemid 40779686)
103. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006;20:679-97 (Pubitemid 44375115)
104. Sun HY, Alexander BD, Lortholary O, et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009;49:1721-8
105. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008;30:167-72 (Pubitemid 351521643)
106. Armstrong-James D. Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J Antimicrob Chemother 2007;60:459-60 (Pubitemid 47299857)
107. Arnold HM, Micek St, Shorr AF, et al. Hospital resource utilization and cost of inappropriate treatment of candidemia. Pharmacotherapy 2010;20:361-8
108. Arnold HM, Micek St, Shorr AF, et al. Hospital resource utilization and cost of inappropriate treatment of candidemia. Pharmacotherapy 2010;20:361-8
109. Hsu DI, Nguyen M, Nguyen L, et al. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother 2010;65:1765-70
110. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008;36:2967-72
111. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007;60:613-18 (Pubitemid 47299877)
112. Zilberberg MD, Kollef MH, Arnold H, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010;10:150
113. Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010;53:95-113
114. Vu K, Gelli A. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii. Med Mycol 2010;48:255-62
115. Blankenship JR, Steinbach WJ, Perfect JR, Heitman J. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Investing Drugs 2003;4:192-9 (Pubitemid 36383016)